Nucletron bolsters cancer radiation position with Isodose merger
This article was originally published in Clinica
Executive Summary
Dutch cancer radiation therapy firms Nucletron and Isodose Control are set to merge and become the leader in the global brachytherapy market. According to Nucletron this complementary deal will merge Nucletron with the number three firm in the sector. Ede-based Isodose was founded by Eric van’t Hooft in 2003 – its products include the Flexitron remote brachytherapy delivery system and Flexiplan brachytherapy planning system. Mr van’t Hooft, who also founded Veenendaal-based Nucletron in 1975, will become a member of the executive management team at the newly-merged Nucletron and will hold the title of founder. Financial terms of the deal were not disclosed.